Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Recommends Caution For Pfizer's Xeljanz

The Agency Has Also Issued Restrictions For Sanofi's Lemtrada

Executive Summary

The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.

You may also be interested in...



EU: Pfizer Warns Doctors About Blood Clot Risk With Xeljanz

Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.

EU Approvals: Rinvoq Cleared For RA

AbbVie’s upadacitinib has become the latest JAK inhibitor to be approved in the EU for active rheumatoid arthritis, and its selectivity could allow it to compete effectively with established therapies including other JAK inhibitors, TNF-inhibiting biologics and biosimilars.

Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval

Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel